In a recent study of short-term treatment with recombinant human growth hormone (rhGH) of HIV-infected men who had lost an average of 19% of their pre-illness weight, we observed marked weight gain, positive nitrogen balance, and a significant increase in protein-sparing fatty acid oxidation. In the studies proposed herein, we will measure body composition (nitrogen and electrolyte balance, bioelectrical impedance, dual energy X-ray absorptiometry, D(2)O dilution), energy expenditure and substrate oxidation (indirect calorimetry), and integrated carbohydrate and lipid metabolism (glucose and lipid tolerance, stable isotope tracer studies) in order to further define the mechanisms by which anabolic agents affect body composition and their potential therapeutic role in AIDS-associated catabolism. Specifically we plan to: 1). determine whether the salutary effects of rhGH that we observed in HIV-infected men can also be achieved in women. Since there are fundamental differences in body composition and lipid metabolism between healthy men and women which may affect the response to catabolic stress, these studies should also elucidate the metabolic consequences of these differences and determine their potential impact on the response to anabolic therapy. 2). determine the effects of chronic treatment with rhGH in patients with AIDS, by performing these metabolic assessments prior to and at the end of three months of treatment. These studies will make it possible to establish the extent to which the strikingly positive nitrogen balance observed with short-term therapy can be sustained during chronic outpatient treatment. 3). determine the potential value of anabolic steroids in the treatment of AIDS-associated catabolism, by characterizing the effects of treatment with nandrolone decanoate (ND), a synthetic derivative of testosterone with a favorable ratio of anabolic to androgenic activity, in normal and HIV-infected men. Since anabolic steroids may cause nitrogen retention without directly affecting whole body lipid and carbohydrate metabolism, a direct comparison of the results of rhGH treatment, which has effects on both protein anabolism and intermediary energy metabolism, with those of ND, which has specific protein anabolic effects, may make it possible to distinguish the role of each process in GH-induced lean tissue accrual. 4). determine whether there are gender differences in the response to anabolic steroids in both healthy and HIV-infected individuals. In view of the pre-treatment differences in endogenous levels of testosterone, we hypothesize that the magnitude of the anabolic response might be even greater in women.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK045833-04
Application #
2145090
Study Section
Diabetes, Endocrinology and Metabolic Diseases B Subcommittee (DDK)
Project Start
1992-09-30
Project End
1997-09-29
Budget Start
1995-09-30
Budget End
1996-09-29
Support Year
4
Fiscal Year
1995
Total Cost
Indirect Cost
Name
University of California San Francisco
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
073133571
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Sakkas, Giorgos K; Schambelan, Morris; Mulligan, Kathleen (2009) Can the use of creatine supplementation attenuate muscle loss in cachexia and wasting? Curr Opin Clin Nutr Metab Care 12:623-7
Sakkas, Giorgos K; Mulligan, Kathleen; Dasilva, Makani et al. (2009) Creatine fails to augment the benefits from resistance training in patients with HIV infection: a randomized, double-blind, placebo-controlled study. PLoS One 4:e4605
Mulligan, Kathleen; Zackin, Robert; Von Roenn, Jamie H et al. (2007) Testosterone supplementation of megestrol therapy does not enhance lean tissue accrual in men with human immunodeficiency virus-associated weight loss: a randomized, double-blind, placebo-controlled, multicenter trial. J Clin Endocrinol Metab 92:563-70
Lo, Joan C; Kazemi, Mahmood R; Hsue, Priscilla Y et al. (2005) The relationship between nucleoside analogue treatment duration, insulin resistance, and fasting arterialized lactate level in patients with HIV infection. Clin Infect Dis 41:1335-40
Lo, Joan C; Mulligan, Kathleen; Noor, Mustafa A et al. (2004) The effects of low-dose growth hormone in HIV-infected men with fat accumulation: a pilot study. Clin Infect Dis 39:732-5
Tai, Viva W; Schambelan, Morris; Algren, Heather et al. (2002) Effects of recombinant human growth hormone on fat distribution in patients with human immunodeficiency virus-associated wasting. Clin Infect Dis 35:1258-62
Napolitano, Laura A; Lo, Joan C; Gotway, Michael B et al. (2002) Increased thymic mass and circulating naive CD4 T cells in HIV-1-infected adults treated with growth hormone. AIDS 16:1103-11
Schwarz, Jean-Marc; Mulligan, Kathleen; Lee, Jeongae et al. (2002) Effects of recombinant human growth hormone on hepatic lipid and carbohydrate metabolism in HIV-infected patients with fat accumulation. J Clin Endocrinol Metab 87:942
Noor, Mustafa A; Seneviratne, Tara; Aweeka, Francesca T et al. (2002) Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS 16:F1-8
Mulligan, Kathleen; Schambelan, Morris (2002) Anabolic treatment with GH, IGF-I, or anabolic steroids in patients with HIV-associated wasting. Int J Cardiol 85:151-9

Showing the most recent 10 out of 31 publications